Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Array BioPharma Spins Off Heart Drug R&D Into New Subsidiary Yarra Therapeutics

Array BioPharma spun off some intellectual property and equipment into a new company, Yarra Therapeutics.

Read More »

Putting the Patient at the Center of Patient-Centric Support Programs

Are marketers just paying lip service to the idea that the patient is in charge when it comes to developing patient acquisition and support programs?

Read More »

Teva Announces Exclusive U.S. Launch of Generic Version of Reyataz

Teva Pharmaceutical Industries Ltd. announced the exclusive launch of a generic version of Reyataz (atazanavir) capsules in the U.S.

Read More »

Odonate Therapeutics Announces Initiation of Phase 3 Study for Metastatic Breast Cancer

Odonate Therapeutics Inc. announced that it has initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer.

Read More »

Anika Announces FDA 510(k) Clearance for Injectable HA-Based Bone Repair Treatment

Anika Therapeutics Inc. announced that its HA-based bone void filler received 510(k) clearance from the U.S. FDA and is indicated for filling bone voids or defects of the skeletal system, which are not intrinsic to the stability of the bone, created during surgery or resulting from traumatic injury.

Read More »

GenScript Biotech Acquires CustomArray to Expand Synthetic Biology Product Portfolio

GenScript Biotech Corp. – a leading global provider of gene synthesis services – announced an agreement to acquire 100 percent of the issued shares of CustomArray Inc., a privately held DNA microarray company.

Read More »

FDA Accepts Sun Pharma’s NDA for OTX-101

Sun Pharmaceutical Industries Ltd. announced the U.S. FDA accepted a New Drug Application (NDA) for OTX-101 (cyclosporine A, ophthalmic solution) 0.09%.

Read More »

Supplements may not lower fracture risk

Older adults who take vitamin D and calcium are no less likely to break their hips or other bones than peers who do not use these supplements per a research review.

Read More »

Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion

Mallinckrodt plc will acquire Sucampo Pharmaceuticals Inc., including its commercial and development assets.

Read More »

Soliris Receives Approval in Japan for gMG

Alexion Pharmaceuticals Inc. announced that the MHLW in Japan approved Soliris (eculizumab) as a treatment for patients with generalized myasthenia gravis.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom